Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with or without a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
Epistemonikos ID: 60c8b828857b7d1622ce6e600ee807de1cad11c4
First added on: Oct 09, 2026